Italian researchers presented another curious research for Acomplia. According to them Acomplia also play a major role in reducing breast cancer. According to Maurizio Bifulco of the Università degli Studi di Salerno, research escorted, Acomplia "inhibited human breast cancer cell proliferation" in both gnawer and test tube studies.
Curiosity began when under discovery it has been found that the Acomplia is the most effective drug to reduce the growth of a belligerent metastatic breast cancer cell line called MBA-MB-231. Metastatic spread of breast tumors pays the majority of cancer related deaths.
The researchers told that "The growth of highly invasive metastatic MDA-MB-231 cells was inhibited more efficaciously than that of less invasive T47D and MCF-7 cells".
According to them they applied different doses of zimulti on tumor cells proliferation against very destructive metastatic, estrogen receptor negative MDA-MB-231 breast cancer cells as well as against estrogen receptor positive T47D and MCF-7 cells and found that the drug is giving the positive response of the reduction of breast cancer.
Experiment:
They have done the test on mice by injecting with MDA-MB-231 cancer cells. After 15 days when tumors were clearly observable, the mice are being injected by rimonabant.
According to researchers under test they have found that "Tumor growth was monitored and the data revealed that exposure to rimonabant led to a significant decrease in tumor mass compared to control-treated mice, and also the treated mice with rimonabant exhibited no outward signs of toxic or hypolocomotor effects".
Under the close surveillance they also found that the CB1 receptor exists in greater extent in some lines of breast cancer than in others and the efficiency of rimonabant depends on the levels of CB1 receptor. So, here the points that should be noted are that the degree of rimonabant use to reduce the breast cancer can be varied.
Under conclusion researchers signified that "The present findings provide unequivocal evidence for the role of the CB1 receptor and its antagonist/inverse-agonis t rimonabant in breast tumor cell proliferation".